Real H Renaud Net Worth

The estimated Net Worth of Real H Renaud is at least $9.58 Milhão dollars as of 3 May 2004. Real Renaud owns over 15,000 units of Charles River Laboratories International stock worth over $9,576,317 and over the last 22 years Real sold CRL stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Real Renaud CRL stock SEC Form 4 insiders trading

Real has made over 3 trades of the Charles River Laboratories International stock since 2003, according to the Form 4 filled with the SEC. Most recently Real exercised 15,000 units of CRL stock worth $79,950 on 3 May 2004.

The largest trade Real's ever made was exercising 15,000 units of Charles River Laboratories International stock on 3 May 2004 worth over $79,950. On average, Real trades about 1,364 units every 8 days since 2003. As of 3 May 2004 Real still owns at least 49,467 units of Charles River Laboratories International stock.

You can see the complete history of Real Renaud stock trades at the bottom of the page.

What's Real Renaud's mailing address?

Real's mailing address filed with the SEC is , , , , .

Insiders trading at Charles River Laboratories International

Over the last 22 years, insiders at Charles River Laboratories International have traded over $220,588,205 worth of Charles River Laboratories International stock and bought 18,392 units worth $3,841,397 . The most active insiders traders include James C Foster, Richard F Wallman, eDavid P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of $2,223,188. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth $354,861.

What does Charles River Laboratories International do?

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro

Complete history of Real Renaud stock trades at Charles River Laboratories International

Charles River Laboratories International executives and stock owners

Charles River Laboratories International executives and other stock owners filed with the SEC include:

• James Foster,
  Chairman of the Board, President, Chief Executive Officer
• David Smith,
  Chief Financial Officer, Corporate Executive Vice President
• James C. Foster,
  Chairman, CEO & Pres
• Joseph LaPlume,
  Corporate Executive Vice President, Corporate Development and Strategy
• Birgit Girshick,
  Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian
• William Barbo,
  Corporate Executive Vice President and Chief Commercial Officer
• David Ross Smith,
  Corp. Exec. VP & CFO
• William D. Barbo,
  Chief Commercial Officer & Corp. Exec. VP
• Joseph W. LaPlume,
  Corp. Exec. VP of Corp. Devel. & Strategy
• Birgit Girshick,
  Corp. Exec. VP & COO
• George Milne,
  Lead Independent Director
• George Massaro,
  Independent Director
• Robert Bertolini,
  Independent Director
• Richard Reese,
  Independent Director
• Richard Wallman,
  Independent Director
• Martin Mackay,
  Independent Director
• Deborah Kochevar,
  Independent Director
• Jean-Paul Mangeolle,
  Independent Director
• Stephen Chubb,
  Independent Director
• Virginia Wilson,
  Independent Director
• Nancy Andrews,
  Independent Director
• George Llado,
  Director
• Matthew L. Daniel,
  Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Todd Spencer,
  Corp. VP of Investor Relations
• Mark Mintz,
  Corp. Sr. VP & Chief Information Officer
• Prof. Julie Frearson Ph.D.,
  Corp. Sr. VP & Chief Scientific Officer
• Michael Gunnar Knell,
  Corp. Sr. VP & Chief Accounting Officer
• John J Crowley,
  SVP, Chief Accounting Officer
• Davide Molho,
  Corporate Executive VP
• Michael Gunnar Knell,
  CSVP&Chief Accounting Officer
• Craig B. Thompson,
  Director
• John W Kuo,
  CEVP General Counsel & CCO
• Victoria L Creamer,
  EVP & Chief People Officer
• David P Johst,
  Corporate Executive VP
• Jorg Geller,
  OFFICERS
• Nancy Gillett,
  Vice President
• Thomas F Ackerman,
  Sr. Vp and CFO
• Samuel O Md Thier,
  Director
• William Waltrip,
  Director
• Nancy T Chang,
  Director
• Christopher Berthoux,
  OFFICERS
• Douglas E Rogers,
  Director
• Real H Renaud,
  Executive Vice President
• Brian Bathgate,
  Corporate Vice President
• Joanne P Acford,
  Corp. Sr VP, GC and Corp. Sec
• David J Elliott,
  Officer
• Linda Mc Goldrick,
  Director
• Stephanie B Wells,
  Senior Vice President
• Cheri L Walker,
  Corporate Senior VP
• Nicholas Ventresca,
  Senior Vice President
• Michael F Ankcorn,
  Corporate Sr. Vice President
• Walter S Nimmo,
  Director
• S Louise Mccrary,
  Director
• John C Ho,
  Senior Vice President
• Alastair Stuart Mcewan,
  Corporate Vice President
• John Urquhart,
  Director
• Dennis R Shaughnessy,
  Sr. VP Corporate Development
• Robert Cawthorn,
  Director
• Flavia Pease,
  Corporate Executive VP & CFO
• Shannon M Parisotto,
  CEVP, Disc & Safety Assessment
• Reshema Kemps Polanco,
  Director